Skip to main content

Home/ Medicine & Healthcare/ Group items tagged followup

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
avivajazz jazzaviva

Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod ... - 0 views

www.mendeley.com/...gterm-followup-study-in-europe

imiquimod aldara recurrence recurrence-rate recurrences pubs pubmed 5-year long-term follow-up treatment conclusion cream study

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. by Harald Gollnick
avivajazz jazzaviva

Mohs surgery in sBCC following treatment with imiquimod 5% cream - 0 views

www.ncbi.nlm.nih.gov/...18569271

mohs aldara imiquimod cream sBCC BCC 2-year 1-year follow-up followup pubs abstract

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Eight of nine individuals, 89% (95% CI 56% to 97%) were histologically clear of sBCC at 52 weeks.
avivajazz jazzaviva

Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week p... - 0 views

www.ncbi.nlm.nih.gov/...19646136

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies 1-year 2-year followup

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Clinical clearance rate at 1 and 2 years were 89% and 85%, respectively.
avivajazz jazzaviva

Has imiquimod 5% cream a role in the management of... [Eur J Dermatol. 2009 Sep-Oct] - ... - 0 views

www.ncbi.nlm.nih.gov/...19527989

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies recurrent refractory 3-year followup

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Clinical clearance rate at 1, 2 and 3 years were 94, 76 and 70%, respectively. We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of recurrent BCC in patients with associated co-morbidities.
avivajazz jazzaviva

Nonsurgical Treatment Options for Basal Cell Carcinoma | Review Article | Journal of Sk... - 0 views

www.hindawi.com/...571734

BCC sBCC studies pubs outcomes efficacy therapy therapies treatment options treatments

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Journal of Skin CancerVolume 2011 (2011), Article ID 571734, 6 pagesdoi:10.1155/2011/571734 © 2011 Mary H. Lien and Vernon K. Sondak.
1 - 5 of 5
Showing 20▼ items per page